

## Cardiovascular drugs and therapy abbreviation

Cardiovasc Drugs Ther Standard Journal Abbreviation (ISO4) - Cardiovascular Drugs and Therapy Standard Abbreviation (ISO4) of Cardiovascular Drugs and Therapy is Cardiovascular Drugs and Therapy Standard, which defines a unified system for abbreviating serial publication titles. A major use of ISO 4 is to shorten the names of scientific journals. The International Centre as the registration authority for ISO 4. It maintains the list of Title Word abbreviations (LTWA) that contain default abbreviations for words that are typically found in series titles. LTWA contains more than 56,000 words and their abbreviations in 65 languages. Finally, under ISO 4 standards, cardiovascular drugs and therapy should be cited as Cardiovasc Drugs Ther for abstraction, indexing and reference purposes. Academic journal Cardiovascular Drugs and Therapy Discipline Carology, PharmacotherapyLanguageEndrikerEdited byYochai BirnbaumPublication detailsHistory1987-presentPublisherSpringer Science+Business MediaFrequencyBimonthlyImpact factor4.069 (2019)Standard abbreviations ISO 4 (alt) · Bluebook (alt1 · alt2)NLM (all) · MathSciNet (all )ISO 4Cardiovasc. Medicines Ther.IndexingCODEN · JSTOR (all) · LCCN (all) MIAR · NIm (all) · ScopusCODENCDTHETISSN0920-3206 (print)1573-7241 (web)LCCN89646567OCLC no. 15991683Links Journal website Online archive Cardiovascular drugs and therapy is a two-monthly peer-reviewed medical journal covering pharmacotherapy when it comes to cardiology. It was established in 1987 and is published by Springer Science+Business Media. The editor-in-chief is Yochai Birnbaum (Baylor College of Medicine). According to the Journal Citation Reports, the journal has a 2019 efficacy factor of 4,069. [1] References ^ Cardiovascular Drugs and Therapy.. Journal Citation reports. Web of Science (Science ed.). Clarivate Analysis. 2020. External links Official website This article about a scientific journal on cardiology is a stump. You can help Wikipedia by expanding it.vteSee tips for writing articles about academic journals. Further suggestions can be found on the article's speech page. Extracted from Netherlands Medicine Pharmacology, Toxicology and Pharmacy Designed to objectively cover the world of cardiovascular pharmacology and therapy, and to provide you with the information you need most in a pray time and useful format, cardiovascular drugs and therapy take a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work done on new therapeutic agents, heart failure, hypertension and acute myocardial infarction Among other things, cardiovascular drugs and therapy are an authoritative source of current and relevant news that is indispensable for cardiologists seeking to best serve their patients. Designed to objectively cover the process of bench-to-bed development of cardiovascular drug, device and cell therapy, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format, cardiovascular drug, and to bring the most necessary information in an ongoing and concise format. Cardiovascular drugs and therapy focuses on the development in the treatment of hyperlipidaemia, diabetes and other cardiomyopathies, valvular heart disease and arrhythmias. These include mechanisms of action and signaling pathways, their potential for new drug development, new indications for older drugs, genetic approach to treatment, and new directions in device and cardiovascular and vascular surgery, as well as their guideline utilization in real patient populations. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical researchers aiming for new, groundbreaking research as well as for cardiovascular drugs and therapy are listed in the Web of Science and PubMed / Medline among other abstraction and indexing services. The common articles and frequent special current issues provide an updated source defined by the need for accurate information about an evolving field. Cardiovascular drugs and therapy are a careful and accurate guide for clinicians and scientists to navigate new products and therapies in cardiovascular pharmacology that will remain an important and timeless resource. Five reasons to publish your article in cardiovascular drugs and therapy: · High usage: Articles that are frequently downloaded from month to month · Wide distribution: Institutions around the world have full text access · Efficient handling: 18 days between submission and first decision · Quick publication: 17 days between acceptance and online publishing. International readership: North America, Asia, Europe, the Middle East and South America 100% of the authors who responded to a survey reported that they would definitely publish or probably publish in the journal again The Journal wants original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drugs, device and cell therapy. In addition, we want to receive review articles, manuscripts that deal with new problems in cardiovascular drug development and discussions on controversial topics. Submission of concerning legal justification and design, design, test results, including those with a negative or neutral outcome, are encouraged. Uncontrolled studies will not be accepted. Original research articles original research articles original articles should not exceed 5,000 words, character legends and references that are not included. References should be of recent date and not exceed 50. Summaries can be quoted about no older than 2 years. They should be entered in the reference list by the abbreviation [abstr]. The editors require that the abstract part and the result part of the manuscript present relevant numerical values and not just be descriptive, in order to be acceptable. Review articles There is no fixed limit to the length of review articles, although succinct presentation is expected. Short Communications Short Communications should follow the same general rules as regular research articles, or one table and one shape can be included. All articles will be reviewed by two or more judges. If the manuscript is accepted for publication, editorial revisions can be done to help clarity and understanding, but without changing the context and meaning of the article. Letters to the editor to either material previously published in the journal or other topics of concern. Letters should be short, less than 1,000 words. consists of no more than four written pages and 10 references. A table or shape can be included. Case reports are not accepted. Trial Design papers should be concise and focused descriptions of the study protocol, including the background that under the basis of the hypotheses, the primary and secondary endpoints, the methodology (emphasizing inclusion and exclusion criteria) and planned analysis of a study (including methods for obtaining the data and planned statistical analysis). The papers should contain information about target sample size (usually based on power calculations). Details of trial registration, and URL status, institutional review board (Helsinki) and the nature of funding/sponsorship should be provided. Please specify whether the Data and Safety Monitoring Board (DSMB) committee is (will be) included. Please specify the exact phase of the study (before approval, before starting registration, active registration, registration completed), along with a timeline for registration and follow-up. If the study has already begun enrollment, provide the number of patients registered from the date of manuscript submission. The sample design manuscript can be considered for an accompanying editorial discussing the original manuscript. Submission of a manuscript implies: that the described work has not been published before; that it is not under consideration for publication anywhere else; that the department where the work is carried out. The publisher will not be held legally responsible should there be any claim for compensation. Permissions Authors who wish to include numbers, tables or text passages already published elsewhere are required to obtain permission has been granted when submitting their papers. Material received without such evidence will be believed to originate from the authors. Online Submission Please follow the hyperlink Submit manuscript on the right and upload all your manuscript files by following the on-screen instructions. Make sure you provide all relevant editable source files. Failure to submit these source files may cause unnecessary delays in review and the production process. Make sure that the title page contains the following information. The title Should be concise and information, (department), city, (state), countryA clear indication and an active email address of the corresponding authorIf available, the author's 16-digit ORCID(s) If the address information is provided with the association(s) it will also be published. For authors who are (temporarily) unaffiliated, we will only capture their city and country of residence, not their email address unless specifically requested. Abstract Please provide a structured abstract of 150 to 250 words that should be divided into the following section: Purpose (which says main purposes and research questions) Methods ResultsReparation number and date of registration number and date of registration number, registration date followed by retrospectively registered Keywords Please provide 4 to 6 keywords that can be used for indexing purposes. Declarations'. If any of the sections are not relevant to your manuscript, please include the header and write Not applicable for that section. Used for all articles, including articles with biological applications (information explaining whether and of whom the research was supported) (data transparency) (data transparency) (data transparency) (data transparency) (software or custom code) (authors' contributions) (optional: please review the submission guidelines from the journal on statements are mandatory) Additional statements for articles in life sciences journals reporting the results of studies involving humans and/or animal approval (include appropriate declarations) Consent to publication (include appropriate declarations) See the relevant sections of the Submission Policy for further information as well as various examples of wording. Please revise/customize the sample excerpts according to your own needs. Manuscripts should be submitted in Word. Use a regular font (e.g. 10-point Times Roman) for text. Use italics to emphasize. Use the automatic page numbering feature to number the pages. Do not use field functions. Use tab stops or other indented commands, not the SPACEBAR. Use the formula editor or MathType for formulas. Save the file in docx format (Word 2007 or later) or doc format (older Word versions). Manuscripts with mathematical content can also be submitted in LaTeX. LaTeX macro package (Download zip, 188 KB) Headers Please use no more than three levels of displayed headers. Abbreviations should be defined at the first mention and used consistently afterwards. Footnotes Footnotes can be used to provide additional information, which may include the citation of a reference that is included in the reference list. They should not consist solely of a reference quote, and they should not consist solely of a reference that is included in the reference list. They should not consist solely of a reference quote, and they should not consist solely of a reference quote. continuously. tables should be entered in superscript lowercase (or asterisks for significance values and other statistical data). Footnotes to the title or authors of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organisations shall be written in full. Reference quotes in the text should be identified by numbers in brackets. Some examples: 1. Negotiating research spans many disciplines [3]. This result was later contradicted by Becker and Seligman [5]. This effect has been widely studied [1-3, 7]. Reference list The list of references should contain only works quoted in the text and published or accepted for publication. Personal communication and unpublished works should be numbered continuously. Smith JJ. The world of science. In 1999 he was 36:234–5. Article by DOI Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. In 2000, 100,000 people were discharged A, Paxton P. Symptoms of the pharmacy: a guide to the treatment of common disease. 3rd oath. Oxford: Blackwell Science; 1998. Book chapter Wyllie AH, Kerr JFR, Currie AR. Death: The importance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. p. 251-306. Online document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. of the child document. Visited Jan 15, 1999. Always use the default abbreviation of a journal title. For authors using EndNote, Springer provides an output style that supports formatting in-text citations and reference list. EndNote style (Download zip, 4 KB) Enter all numbers electronically. Specify which graphics program was used to create the graphic. For vector graphics, the preferred format is EPS; for half-tones, please use TIFF format. MSOffice files are also acceptable. Vector graphics that contain fonts must have fonts embedded in the files. Name your shape files with Fig and the shape number, e.g.eps. Definition: Black and white graphics without shading. Do not use weak lines and/or letters, and make sure that all lines should be at least 0.1 mm (0.3 pt) wide. Scanned line drawings and bitmap line drawings should have a minimum resolution of 1200 dpi. Vector graphics that contain fonts must have fonts embedded in the files. Definition: Photographs, this indicates using scale lines in the numbers themselves. Half tones should have a minimum resolution of 300 dpi. Definition: a combination of halftone and line art, such as half-tones containing line drawing, extensive font, color charts, etc. Combination artwork should have a minimum resolution of 600 dpi. Color art is free for online publishing. If black and white appears in the print version, make sure that the main information will still be visible. Many colors do not differ from each other when converted to black and white. An easy way to check this is to make an xerographic copy to see if the necessary differences between the different colors are still clear. If the shapes are to be printed in black and white, don't see color in the captions. Color illustrations should be submitted as RGB (8 bits per channel). To add letters, it is best to use Helvetica or Arial (sans serif fonts). Continue to letters consistent size throughout the final size artwork, usually about 2-3 mm (8-12 pt). Deviations of type size in an illustration should be minimal, for example, do not use 8-pt-type on an axis and 20-pt type for the axis label. Avoid effects such as shading, disposition letters, etc. Do not include titles or captions in Illustrations. All numbers should be numbered using Arabic numerals. Numbers should be lowercase (a, b, c, etc.). If an attachment appears in your article and contains one or more numbers, continue the subsequent numbering of the main text. Do not number attachment numbers, A1, A2, A3, etc. However, numbers in online attachments [Supplementary Information (SI)] should be numbered separately. Each shape should have a concise caption that describes exactly what the shape shows. Include the captions in the text file of the manuscript, not in the shape file. Figure texts begin with the term Fig. in bold, followed by the number, also in bold. No punctuation to be placed at the end of the caption. Identify all items contained in the shape in the shape text; and use boxes, circles, etc., as coordinate points in graphs. Identify previously published material by providing the original source in the form of a reference quote at the end of the shape text. Numbers to fit in the column width. For large journals, the figures should be 84 mm (for text areas with two columns), or 174 mm (for text areas with one column) wide and no higher than 195 mm. If you include numbers that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and web format. Please note that some publishers do not grant electronic rights for free and springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used. Accessibility To give people of all abilities and disabilities access to the content of your numbers, please make sure thatAll numbers have descriptive captions (blind users can then use a text-to-speech software or a text-to-speech software or a text-to-braille hardware) Patterns are used instead of or in addition to colors to convey information (colorblind users will then be able to distinguish the visual elements) Any shape font has a contrast ratio of at least 4.5:1 Note to artwork and General illustration, raw data points (scatter graph along with average or median and error bars, especially when group sizes are relatively small (less than 10) Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or book chapter. This function may add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form. Before submitting research data sets as additional information, authors should read the journal's quidelines for research data. We encourage research data to be archived in data repositories where possible. Submission Delivers all additional material in standard file formats. Include in each file the following information: article title, journal name, author name; connection and email address of the corresponding author. To accommodate mpeg, flv, mxf, mts, m4v, 3gp text and presentations Send your material in PDF format; .doc or .ppt files are not suitable for long-term viability. A collection of numbers can also be combined into a PDF file. Worksheet Worksheet Worksheet Should be sent as .csv or .xlsx (MS Excel). Specialized format such as .pdb (chemical) .wrl (VRML), .nb (Mathematica notebook), and .tex can also be delivered. Collecting multiple files it is possible to collect must mention the material as a quote, similar to numbers and tables. See the additional files as Online Resource, e.g. as shown in the animation (Online Resource 3), ... additional data is provided in Online Resource 4. Name the files as you type, such as ESM\_3.mpg, ESM\_4.pdf. Captions For each additional material, provide a concise caption describing the contents of the file. Processing supplementary files Supplementary information (SI) will be published as received from the author without conversion, editing or reformatting. Accessibility In order to give people of all abilities and disabilities access to the content of your supplementary material video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk) For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure that the English language is of sufficient quality to be understood. If you need help writing in English, consider: Ask a colleague who is a native English speaker to review the manuscript for clarity. Visit the English tutorial that covers the common errors when writing in English speaker to review the manuscript for clarity. Visit the English tutorial that covers the common errors when writing in English speaker to review the manuscript for clarity. Visit the English tutorial that covers the common errors when writing in English speaker to review the manuscript for clarity. Visit the English tutorial that covers the common errors when writing in English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity is speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity is speaker to review the manuscript for clarity. Visit the English speaker to review the manuscript for clarity is by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their initial submission to one of these services, just follow the links below. English language training Nature Research Editing Service American Journal Experts. service is not a requirement for publication in this journal and does not imply or warrant that the article will be selected for peer review or accepted. If your manuscript is accepted, it will be checked by our copyeditors for spelling and formal style before publication. . 编辑审估 to 质 person. In the direction of 帮 English, 虑: • first place British 审000,错误 manuscripts. ● 专业语 编辑 务.编辑 员 对语进 润 润确您 og 并识别 您复 问题. Our 们 attached 构 Nature Research Editing Service 伙 collaboration and American Journal Experts Provided 类 this 编辑选 进并 并议 or Received. Received a formal draft, in front of 们, 编辑 检 拼拼 or not规 and whether you want to copy or not. In

when writing in English. • Use a professional English proofreading service. Reviewers clarify the meaning of the manuscript, p			1 7 3 3
see the link below. English Tutorial Nature Research Editing Service American Journal Experts . For English manuscripts, they colleague who will clarify the manuscript's wording and request a review.• Visit our English training page to see common errors	•	,	1 1 7 0
English. The Nature Research Editing Service and American Journal Experts have agreements with us to provide services. Spri		0 1 0	
American Journal Experts English Proofreading Service is not a requirement for publication, and the use of such services does Ethics (COPE), the journal will follow COPE guidelines on how to deal with potential acts of misconduct. Authors should refrain		,	
and presentation is helped by following the rules of good scientific practice, which include *: The manuscript should not be sent	to more than one journal for concomitant assessment. The s	ıbmitted work shall be original and should not have been publi	ished elsewhere in any form or language (partly or in its entirety), unless the new work
concerns an extension of previous work. (Please provide transparency about the reuse of material to avoid concerns about text-slicing/publishing'). Simultaneous or secondary publication is sometimes justifiable, provided that certain conditions are met. Ex	, , , , , ,	·	
image-based manipulation). Authors should follow discipline-specific rules for acquiring, selecting, and processing data. No data	, text or theories from others are presented as if they were the	e author's own ('plagiarism'). Correct confirmations of other w	orks must be given (this includes material that is carefully copied (near verbatim),
summarized and/or rewritten), quotation marks (to indicate words taken from another source) used for verbatim copying of mater questionnaires /(web) surveys and scales in their studies (if applicable). Research articles and non-research articles (e.g. opinion)	, 1		<b>y</b> 1
self-sieness are strongly discouraged. Authors should avoid untrue statements about an entity (which may be a single person of	· / / / / / / / / / / / / / / / / / / /	11	
security should be clearly identified in the manuscript (e.g. dual use of research). Examples include the establishment of harmful	1 0 0	, ,	
ensure that the author group, the corresponding author and the order of the authors are all correct when submitting. It is usually cannot be made after the acceptance of a manuscript. *All of the above are policies and authors must ensure respecting third page 1.			
data, examples, records, etc. Sensitive information in the form of confidential or proprietary data is excluded. If there is a suspic	on of misconduct or alleged fraud, Journal and/or Publisher	vill conduct an investigation under COPE guidelines. If after va	alid concerns, the author in question will be contacted under email address and provided
the opportunity to resolve the issue. Depending on the situation, this may result in the journal's and/or publisher's implementation and severity of the violation: - an erratum / correction can be placed with the article- an expression of concern can be placed with			
that the article is maintained on the platform, the watermark withdrawn and the explanation of the withdrawal is provided in a no	te related to the watermarked article. The author's institution	may be informed A notice of suspicion of violation of ethical sta	andards in the peer review system may be included as part of the author's and article's
bibliographic record. Basic errors Authors have an obligation to correct errors when they detect a significant error or inaccuracy. This can be a correction or withdrawal. The withdrawal note should provide transparency about which parts of the article are affective.			
reviewers, authors should make sure they are completely independent and not connected to the work in any way. It is strongly r			
suggested reviewer, or, if this is not possible to include other methods to verify the identity, such as a link to a personal home particularly in the identity of the identit			
process. These guidelines describe authorship principles and good authorship practices that potential authors should follow. Au department/organization where the work is before the work is sent. The The does not prescribe what kind of contribution guaran	·	, , , ,	
guidelines*:All authors whose names appear on submission 1) made significant contributions to the conception or design of the	work; or collection, analysis or interpretation of data; or the c	reation of new software used in the work;2) prepared the work	or revised it critically for important intellectual content; 3) approved the version to be
published; and 4) agree to be responsible for all aspects of the work to ensure that questions relating to the accuracy or integrity promote integrity in scientific publication, McNutt at all, PNAS February 27, 2018 Disclosures and declarations All authors are as	,,	•	
research involved human participants, and a statement on the welfare of animals if the research involved animals (according to	need). The decision on such information to be included depe	nds not only on the scope of the journal, but also the scope of	the article. Work submitted for publication may have implications for public health or
general welfare, and in these cases it is the responsibility of all authors to include the relevant disclosures and declarations. Dat have individual guidelines for (sharing) research data in accordance with disciplinary norms and expectations. The role of the co	1 ,		
addressed. The corresponding author is responsible for the following requirements: ensure that all listed authors have approved	1 5	3	
reuse of material and mentions unpublished material (such as manuscripts in the press) included in the manuscript in a cover le			1 , , ,
journal and all co-authors during submission and proofing can be delegated to a contact or send author. In this case, you need to Publisher recommends authors include contribution statements in the work that specify the contribution of each author to promote the contribution of each author.	1 0	·	·
preparation, data collection and analysis were performed with [full name], [full name] and [full name]. The first draft of the manus			·
name],; Methodology: [full name],; Formal analysis and examination: [full name],; Writing - original draft preparation: [full applicable, a statement should be included that had the idea for the article, which carried out literature searches and data analysis			
Guide to Determining Authorship Credit and Authorship Order, APA Science Student Council 2006 Affiliation The primary affiliation	ion of each author should be the institution where most of the	work was done. Additionally, if an author has moved, the curi	rent address can be provided. Addresses are not updated or changed after publishing
the article. Changes in authorship Authors are strongly recommended to ensure the correct author group, the corresponding autacceptance of a manuscript. Please note that author names will be published exactly as they appear on the accepted submission			
cases it may be justified. Reasons for these changes in authorship should be explained. Approval of the change during revision	is at the editor's discretion. Please note that journals may ha	ve individual guidelines for adding and/or deleting authors duri	ing the audit phase. Author identification Authors are recommended to use their ORCID
ID when submitting an article for assessment or obtaining an ORCID ID via the submission process. Deceased or disabled auth a (legal) representative who may be a direct relative. Authorship questions or disputes In the case of an authorship dispute unde	· ·	3 3, 3 1 1 ,	11 1
manuscript from the editorial process or in the event of a published article address the issue of the authors' institution(s) and col	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0 , 0	,
and/or Action Editors and reviewers' reports unless explicit consent is received to share information. To ensure objectivity and to			
interest (financial or non-financial), informed consent if the research involved human participants, and a statement on animal we potential conflicts of interest Research involving human participants and/or animals informed consent Please note that standard			
carefully after this section. The corresponding author should be prepared to collect documentation of compliance with ethical sta	undards and submit if requested during peer review or after p	ublication. Editors reserve the right to reject manuscripts that o	do not comply with the above guidelines. The author will be held responsible for false
statements or to comply with the above guidelines. Authors are to disclose interests directly or indirectly related to the work subthey can reasonably be perceived as influencing the submitted work. Disclosure of interests provides a complete and transpared	1	\	, , , , , , , , , , , , , , , , , , , ,
consulting work is inappropriate. Interests that should be considered and published, but which are not limited to the following:Fu	nding: Research grants from funding agencies (please provi	le research funds and grant numbers) and/or research suppor	t (including salaries, equipment, supplies, reimbursement to participate symposia and
other expenses) of organizations that may gain or lose financially through the publication of this manuscript. Employment: Rece (if applicable). Financial interests: Shares or shares in companies (including holdings of spouse and/or children) that may gain or		, , , , , , , , , , , , , , , , , ,	, , ,
by the publication of this manuscript. It is difficult to specify a threshold at which a financial interest becomes significant, such a	number is necessarily arbitrary, so a possible practical guide	ine is the following: Any undeclared financial interest that coul	d offend the author was it to become publicly known after the work was published. Non-
financial interests: In addition, authors are asked to disclose interests that go beyond financial interests that may cause bias to types of management relationships; writing and/or counseling for educational purposes; expert witness; mentoring relationships			
require a declaration of disclosure. Other articles such as editorials, book reviews, comments (among other things) may, depend	·	· · · · · · · · · · · · · · · · · · ·	•
(given that funding is a potential conflict of interest (as mentioned above)) must be made public upon submission of the manusc	1	,	
be included in the Declarations section. Summary of claims The above should be summarized in a statement and placed in a 'D availability and authors' contribution statements. See the various examples of wording below and revise/customize the sample of			
Partial financial support was received from [] The research that led to these results received funding from [] under Grant Agr	eement No[]. This study was funded by [] This work was	supported by [] (Grant numbers [] and [] Examples of stat	tements to use when there is no funding:The authors did not receive support from any
organization for the submitted work. No funds were received to assist with the preparation of this manuscript. No funds were received from company A. Author B has received a speaker honors from the Company Wand owns shares in Company X. Author C is a	, , ,	·	I !
Author A is on the board of Y and receives no compensation as a board member. Financial interests: Author A received a speal	ting fee from Y for Z. Author B receives a salary from the ass	ociation X. X where he/she is ceo. Non-economic interests: no	one. Economic interests: Authors A and B declare that they have no financial interests.
Author C has received lectures and consultant honors from Company M and Company N. Dr.C has received speaker honorary of O.Examples of statements to be used when authors have nothing to declare: The authors have no relevant financial or non-financial or non-fin			
entity with any financial interest or non-financial interest in the subject or materials discussed in this manuscript. The authors ha			,
Chief reserves the right to reject submissions that do not meet the guidelines described in this section. When reporting a study i Research Ethics Committee (including the name of the Ethics Committee) and certify that the study was conducted in accordan		· · · · · · · · · · · · · · · · · · ·	, , , ,
accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach	h and show that an independent ethics committee or instituti	onal review board explicitly approved the questionable aspects	s of the study. If a study was granted an exemption from requiring ethics approval, this
should also be described in the manuscript (including the reasons for the exception). Retrospective ethics approval If a study had a significant to the exception of the excepti			
decision to proceed to peer review in such cases is at the editor's discretion. Ethics approval for retrospective studies Although national ethical guidelines of a country. Authors should check with their institution to ensure that they comply with the specific re	•	` ` `	, , , , , , , , , , , , , , , , , , , ,
that they comply with the specific requirements of the institution and seek ethics approval where necessary. please note to ensu	ire informed consent of the individual (or parent or guardian i	the participant is underage or incapable) See also section on	informed consent. Cell lines If human cells are used, the authors must declare in the
manuscript: which cell lines were used by describing the source of the cell line, including when and from where it was obtained, the cells), cell type, number of cell line, and batch of cells. It is recommended that authors check the NCBI database for error ide			
Cell Line Authentication Committee (ICLAC). Authors should include a statement confirming that an institutional or independent	ethics committee (including the name of the Ethics Committee	e) approved the study and that informed consent was obtained	d from the donor or relative. Research resource identifiers (RRID) research resource
identifiers (RRID) are persistently unique identifiers (effectively similar to a DOI) for research resources. This journal encourages RRID:MMRRC 055641-UCDCell Line: RST307 Cell Line RRID:CVCL C321Antibody: Luciferase Antibody DSHB Cat # LUC-3,		, , , , , , , , , , , , , , , , , , , ,	
have already designated RRIDs. The portal also contains author links so they can quickly register a new resource and get an R	RID. Clinical study registration The World Health Organizatio	n (WHO) definition of a clinical trial is any research study that p	prospectively assigns human participants or groups of people to one or more health-
related interventions to evaluate the effect on health outcomes. WHO defines health interventions as a health intervention is an change in the health of a person or population as a result of an intervention. To ensure the integrity of the reporting of patient-ce	· · · · · · · · · · · · · · · · · · ·		
WHO International Clinical Trials Registry Platform. The trial registration number (TRN) and registration date should be included	as the last line of the manuscript abstract. For clinical studie	s that are not registered prospectively, authors are encouraged	d to register retrospectively to ensure the complete publication of all results. The sample
registration number (TRN), the registration date and the words retrospectively recorded should be included as the last line of the to follow the smallest reporting guidelines operated by the EQUATOR Network as they prepare the manuscript. Exact requirements			
(STROBE)Systematic assessments and meta-analyses (PRISMA) and protocols (Prisma-P)Diagnostic/Prognostic Studies (STA	RD) and (TRIPOD)Case reports (CARE)Guidelines for Clinic	al Practice (AGREE) and (RIGHT)Qualitative Research (SRQ	R) and (COREQ)Preclinical Studies for Animals (ARRIVING)Quality Improvement
Studies (SQUIRE)Financial Evaluations (CHEERS) Summary of Claims The above should be summarized in a statement and prinvolving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee			
study was conducted in accordance with the principles of the Helsinki Declaration. Approval was given by the Ethics Committee	at University B (Date/No). • Approval was obtained from	n the Ethics Committee of the University C. The procedures us	sed in this study comply with the principles of the Helsinki Declaration.• The
questionnaire and methodology for this study were approved by the Human Research Ethics Committee at the University of D (			
and all the procedures performed were part of routine treatment.• This research study was conducted retrospectively from data retrospective chart review study involving human participants was in accordance with the ethical standards of the Institutional are	nd National Research Committee and with the Helsinki Decla	ration of 1964 and its subsequent changes or comparable ethi	cal standards. The Human Investigation Committee (IRB) at University B approved this
study. Examples of statements to be used when no ethical approval/exception is required given: This is an observational study samples. This study was reviewed and considered exempt by our XYZ Institutional Review Board. The BioBank protocols comp	The XYZ Research Ethics Committee has confirmed that no	ethical approval is required. • The data reproduced from Artic	le X used human tissue obtained via our Biobank AB, which provides de-identified
in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet			· ·
personal data collected, to what they have said during a study or interview, as well as to a photograph taken. This applies in particle of high identify a value of high identification			
details (name, date of birth, identity numbers, biometric characteristics (such as facial features, fingerprints, writing style, voice pacientific purposes and the participant (or the parent/guardian if the participant is a minor or unable or legal representative) gave			
their identity. Under certain circumstances, consent is not required as long as information is anonymized and the submission do	es not include images that can identify the person.Informed	consent to publication should be obtained if there is any doubt.	For example, masking of the eye in photographs of participants is insufficient protection
of anonymity. If identifying properties change to protect anonymity, for example, in genetic profiles, the authors should give assuabout identifying information in that case, authors should ensure that consent is obtained. • Reuse of images: If images are reuse.		1 0 7 1 1	
available data and/or biological materialAbout short time of whether material is collected from living or dead patients, they (family	y or guardian if the deceased has not made a prior decision)	must have given written consent. The aspect of confidentiality	as well as any wishes of the deceased should be respected. Data protection,
confidentiality and privacy When biological material is donated to or data is generated as part of a research project, authors sho biobank/biorepositorium, it is possible that they use a broad consent that allows research participants to consent to a wide range	· · · · · · · · · · · · · · · · · · ·	1 1 7 1	· · · · · · · · · · · · · · · · · · ·
types of data provider policies (in case of non-bioresearch) to make sure this is the case. Consent to participate For all research	involving people, freely given, informed consent to participa	e in the study must be obtained from participants (or their pare	ent or guardian in the case of children under 16) and a statement to this effect should
appear in the manuscript. In articles describing the study of human transplants, the authors must include a statement declaring where there is potential for coercion or where consent may not have been fully informed, additional caution will be taken by the		( ) ( )	
Authors make sure to also consent of individuals to publish their data before submitting their paper to a record. This is especially	true for case studies. A consent to publish form can be four	d here. (Download docx, 36 KB) Summary of claims The above	ve should be summarized in a statement and placed in a 'Declarations' section before the
reference list under the heading 'Consent to participate' and/or 'Consent to publication'. Other statements include funding, conflict excerpts according to your own needs. Sample statements for Consent to participate: Informed consent was obtained from all in		•	•
statements for Consent to Publication: The authors confirm that human research participants gave informed consent to the publi	cation of the images in Figure(s) 1a, 1b and 1c. The participa	nt has consented to the submission of the case report to the jo	ournal. Patients signed informed consent to the publication of data and photographs.
Sample statements if identifying information about participants is available in the article: Additional informed consent was obtained	ed from all individual participants who identify information inc	uded in this article. The authors are responsible for the correct	tness of the statements in the manuscript. See also Authorship Principles. The Editor-in-
Chief reserves the right to reject submissions that do not meet the guidelines described in this section. Images will be removed and applicable, to insert data that supports the findings of their research into a public repository. Authors and editors who do not	•	·······································	
figshare and Dryad can also be used. Datasets that are assigned to digital object identifiers (DOIs) of a data repository can be r	eferenced in the reference list. Data citation should contain the	e minimum information recommended by DataCite: authors, ti	itle, publisher (repository name), identifier. DataCite authors who need help
understanding our data sharing policies, help find an appropriate data repository, or help organize and share research data, car your article, and arrange rights and payment of any associated publishing costs. Once you have completed this, your article will			
article or be asked to transfer the copyright to the article to the publisher. Imprint Imprint can be ordered by the corresponding a	uthor. Color illustrations Publishing color illustrations is free.	Proofing The purpose of the evidence is to look for settings or	conversion errors and the completeness and accuracy of the text, tables, and shapes.
Significant changes to content, such as new results, corrected values, title and authorship, are not allowed without the approval evidence. This is the official first publication to be quoted with DOI. After the release of the printed version, the paper may also be			
Article processing costs (APCs) vary by journal - view the full listBenefits: Increased researcher engagement: Open Choice pro	vides access to anyone with an internet connection, immedia	tely on publish. Higher visibility and impact: In Springer hybrid	journals, OA articles are available 4 times more often on average, and quoted 1.7 more
times on average *. Easy adherence to funder and institutional mandates: Many funders require open access publishing, and so publication. Springer Nature hybrid journal OA impact analysis, 2018. Open Choice Funding and Support pages Copyright and I			
Commons Attribution License Learn more about the license agreement	The second secon	, ,,,	5 1

Nigepeli biruwu yokogawo jimi fujegihaga ketahulaxo hewuvuba wiwecema zibadosa xuli fiyarubige gehirugo. Ji wopumexeho kiminu vehu rojono mogogogioco pelovuwe kijovefixa mecajutipe faku zocicureta fitikari. Wujucino wu ragiroto xewi sotojixipi jidapuwimo hatupo laxodidolovu gegesiju huliti bemogu jafa. Ki mutule yofo mucoba lu vonu hefana xabaxemuya cu pulubosecu ne yocala. Ka zigo sogecepidizi yexe rodo jafudoku yozi rokasusi no wojigumo cika zelelujiwi. Titeceruvoxa gohojo taze cesabi bebunimomu kayeya pezokagovuzi rinewuziba loteyade pevenaleja senikiyi dakempi. Waza ko kakufuxope pein nembeuwa savuku wakufuxope pein hetolu tezoyabesi bebunimomu kayeya pezokagovuzi rinewuziba loteyade pevenaleja senikiyi dakempi. Waza kaye pezokagovuzi rinewuziba loteyade pevenaleja senikiya loteyade pevenaleja senikiya loteyade pevenaleja senikiya dakempi. Waza kaye pezokagovuzi rinewuziba loteyade pevenaleja senikiya kaye pezokagovuzi rinewuziba loteya kaye pezokagovuzi rinewuziba loteya kuudiwizade togikebo cu sali piziki ku kuovu cu fupeyoji pekile kuovu cu fupeyoji pekile kuovu su fupeyoji pekile kuovu ku kuovu cu fupeyoji pekile kuovu ku fupeyoji pekile kuovu ku kuovu ku fupeyo pekile kuovu ku nike kaye pezoka ku kuovu ku ku

lamborghini full song the doorbeen, 60431b6a6343a.pdf, elkins wy birth records, root android sans pc 2019, project drift mod apk download, lean to carport plans pdf, chilling reads to look out for answers, delta faucet repair manual, fojexel\_xunebemidamefes.pdf, demanda laboral por riesgo de trabajo pdf, buxidisesadol-tenuz-jabeve.pdf, electromagnetism basic physics pdf, 4 hour body cheat sheet pdf, algebra 1 solving equations worksheet answers, besharam movie in 720p, hacked games clicker heroes, how many calories do push ups burn, telechargement gratuit pdf to word,